MAPT and tauopathy: In order to more effectively assess the efficacy of these types of therapeutics in vivo, we designed and generated transgenic animals that encode human 4R tau, containing the P301L mutation which is associated with FTD, that is fused in-frame to luciferase for the purpose of generating transgenic mice that could be used to report the efficacy of knockdown therapeutics in a mouse model of tauopathy.